-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SBHAUIABVxT6tNH/X6N3tRb88l4c8Xq17xv5oejtUlG9bnUmyMo2BZtOo31KWrBG lyxSKOkmHbbIPsbbUqUOAw== 0001193125-09-004550.txt : 20090112 0001193125-09-004550.hdr.sgml : 20090112 20090112111517 ACCESSION NUMBER: 0001193125-09-004550 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090109 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers FILED AS OF DATE: 20090112 DATE AS OF CHANGE: 20090112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ZYMOGENETICS INC CENTRAL INDEX KEY: 0001129425 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 911144498 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-33489 FILM NUMBER: 09520798 BUSINESS ADDRESS: STREET 1: 1201 EASTLAKE AVENUE E CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-442-6600 MAIL ADDRESS: STREET 1: 1201 EASTLAKE AVENUE E CITY: SEATTLE STATE: WA ZIP: 98102 8-K 1 d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 9, 2009

ZYMOGENETICS, INC.

(Exact Name of Registrant as Specified in Charter)

 

Washington   000-33489   91-1144498
(State or Other Jurisdiction of Incorporation)   (Commission File No.)   (I.R.S. Employer Identification No.)

1201 Eastlake Avenue East, Seattle, Washington 98102-3702

(Address of Principal Executive Offices, including Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 442-6600

 

 

 

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Effective January 9, 2009, the Board of Directors (the “Board”) of ZymoGenetics, Inc. (“ZymoGenetics”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), increased the size of the Board from nine to ten members and elected Douglas E. Williams, Ph.D., to the newly created vacancy. Dr. Williams’ term as director will expire at the ZymoGenetics’ 2009 Annual Meeting of Shareholders.

Effective January 2, 2009, Dr. Williams began serving as the Chief Executive Officer of ZymoGenetics and will receive no separate compensation from ZymoGenetics for his services on the Board. On November 24, 2008, ZymoGenetics filed a Form 8-K with the Securities and Exchange Commission, which is incorporated herein by reference, to report the appointment of Dr. Williams as Chief Executive Officer of ZymoGenetics and other information related to Dr. Williams.

Dr. Williams has not been named to any committees of the Board.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ZYMOGENETICS, INC.
Dated: January 12, 2009     By:   /s/ James A. Johnson
      James A. Johnson,
      Executive Vice President,
      Chief Financial Officer
 -----END PRIVACY-ENHANCED MESSAGE-----